Freeman S.M., Whartenby K.A., Freeman J.L., Abboud C.N. and Marrogi A.J., 1996; In situ use of suicide genes for cancer therapy. Sem. Oncol.; 23, 31-45.
Moolten F.L., 1986; Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res.; 46, 5276-5281.
Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H. and Blaese R.M., 1992; In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science; 256, 1550-1552.
Freeman S.M., Abboud C.N., Whartenby K.A., Packman, C.H., Koeplin D.S., Moolten F.L. and Abraham G.N., 1993; The "bystander-effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res.; 53, 5274-5283.
Lechanteur C., Princen F., Lo Bue S., Detroz B., Fillet G., Gielen J., Bours V. and Merville M.-P., 1997; HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Ther.; 4, 1189-1194.
Markowitz D., Goff S. and Bank A. 1988; Construction and use of a safe and efficient amphotropic packaging cell line. Virol.; 167, 400-406.
